Winton Group’s Novartis NVS Stock Holding History

Winton Group’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$371K	Buy	+2,600	New	+$394K	0.01%	763

Other funds holding NVS

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Natixis Advisors Boston, Massachusetts $94.1B AUM 31.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return

Winton Group's NVS Position: Q3 2026 in Review

Winton Group opened a new position in Novartis (NVS) in Q3 2026: 2,600 shares worth $371K. The stake represents 0.01% of the portfolio and ranks #763 among its holdings.

1,370 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

Winton Group held 2,600 shares of Novartis worth $371K as of Q3 2026.
Novartis was a new Winton Group position in Q3 2026.
Novartis made up 0.01% of Winton Group's portfolio in Q3 2026, its #763 holding.
1,370 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Winton Group's 13F filing for Q3 2026, filed 12 Nov 2026.